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Macaques are the only animal model used to test dengue virus (DENV) vaccine candidates. Nevertheless, the
pathogenesis of DENV in macaques is not well understood. In this work, by using Affymetrix oligonucleotide
microarrays, we studied the broad transcriptional modifications and cytokine expression profile after infecting
rhesus macaques with DENV serotype 1. Five days after infection, these animals produced a potent, innate
antiviral immune response by inducing the transcription of signature genes from the interferon (IFN) pathway
with demonstrated antiviral activity, such as myxoprotein, 2,5-oligoadenylate synthetase, phospholipid
scramblase 1, and viperin. Also, IFN regulatory element 7, IFN-stimulated gene 15, and protein ligases linked
to the ISGylation process were up-regulated. Unexpectedly, no up-regulation of IFN-, -, or - genes was
detected. Transcription of the genes of interleukin-10 (IL-10), IL-8, IL-6, and tumor necrosis factor alpha was
neither up-regulated nor down-regulated. Results were confirmed by real-time PCR and by multiplex cytokine
detection in serum samples.
Dengue virus (DENV) is the second most important arthro-
pod-borne tropical disease after malaria, with 50 to 100 million
and 500,000 cases of dengue fever (DF) and dengue hemor-
rhagic fever (DHF)/dengue shock syndrome (DSS), respec-
tively, each year (29). These diseases are induced by DENV, a
member of the Flaviviridae family that exists as four different
serotypes (DENV-1, -2, -3, and -4). The mechanisms of
DENV-induced disease and immune response are not fully
understood, but two theories are the most discussed. The the-
ory of antibody-dependent enhancement postulates that higher
viremia occurs in secondary infections due to antibody-facili-
tated viral entry, causing more severe disease (32–35, 71). The
cytokine-mediated immunopathology theory proposes a model
of plasma leakage in DHF mediated through an interaction
between DENV-infected monocytes/macrophages and mem-
ory CD4 and CD8 DENV-reactive T cells (58–61, 90, 91).
This interaction leads to production of type 1 proinflammatory
cytokines, mainly gamma interferon (IFN-) and tumor necro-
sis factor alpha (TNF-), which directly affects the vascular
endothelium. This cytokine-mediated proinflammatory re-
sponse is postulated to be more extended in a secondary in-
fection than in primary infections due to the preferential ex-
pansion of memory T cells that recognize cross-reactive
epitopes. However, it is well documented that DHF/DSS can
occur after a single DENV infection (6, 7, 13, 50, 64, 77, 83,
108). In addition to IFN- and TNF-, other cytokines, such as
interleukin-18 (IL-18), IL-6, IL-2, and IL-10, have been de-
tected in the sera of patients with DHF (6, 12, 22, 77, 82, 83).
A pathogenic role has been assigned to monocytes/macro-
phages but also to B cells in humans (67). There is no appro-
priate animal model for DENV that reproduces DF/DHF/DSS
symptoms. Recently, some interesting approaches have been
taken using mice as a model (8, 99). However, in spite of its
worth and the advance it represents in the study of DENV,
macaques continue to be the standard model to test vaccine
candidates or treatments against DENV. At present, there is
no specific anti-DENV treatment, but several DENV vaccine
formulations are being studied. All of them have been or will
be tested using macaques before studies are conducted with
humans (11, 21, 38, 84, 85, 87, 88, 102, 105). Previous work has
been performed to characterize DENV replication in ma-
caques (36, 37). However, little is known about the molecular
mechanism of the macaque’s immune response to DENV. In
particular, the type or level of cytokines produced during
DENV infection or the gene expression profile of infected cells
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is not known in these animals. The efficacy of DENV vaccine
trials relies on the production of neutralizing antibodies after
vaccination that can counteract viremia after challenge. Ma-
caques do not develop symptoms that mimic the clinical out-
comes of DF or DHF/DSS in humans, and only a transient
viremia occurs without the development of relevant symptoms.
This suggests a natural mechanism that might allow rhesus
macaques to antagonize DENV infection better than humans.
We have taken preliminary steps to better understand the
innate immune response in rhesus macaques. Here, we have
tested the profile of gene activation and cytokine production
after infecting four rhesus macaques with a low-passage strain
of DENV-1. Our studies provide the first evidence that rhesus
macaques respond to DENV infection with a potent innate
antiviral immune response although without measurable type I
or II IFN or proinflammatory cytokine production in periph-
eral blood mononuclear cells (PBMC). These profiles are quite
different from those reported for humans and could explain the
absence of symptoms of DF or DHF/DSS in these animals.
These findings have implications for vaccine efficacy studies in
progress.
MATERIALS AND METHODS
Infection of animals and blood collection. Six male rhesus macaques that were
negative for immunoglobulin G (IgG) and IgM antibodies to DENV were used
for the study. Four animals were infected subcutaneously with a 1-ml suspension
containing 1  104 PFU of a low-passage Western Pacific 74 DV1 strain (L.
Markoff, Walter Reed Army Hospital). Two animals were mock infected with
supernatant from uninfected LLCMK-2 cells. Sera were collected at days 1, 3,
and 5 after infection, quick-frozen, and kept at 80°C until analysis. On day 5,
PBMC were also collected using 8-ml Vacutainer CPT tubes (BD, Franklin
Lakes, NJ). Tubes were centrifuged at 1,500  g for 30 min at 20°C. Collected
PBMC were washed twice with phosphate-buffered saline, and platelets were
removed by centrifugation at 200  g for 15 min at 20°C. PBMC were used
directly for magnetic cell sorting. A fraction was frozen at 80°C for further
RNA extraction. All work with animals was conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations relating to the use
of animals in research. In addition, all procedures were reviewed and approved
by the Institutional Animal Care and Use Committee at the Medical Sciences
Campus, University of Puerto Rico, and performed in a facility accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care.
Serologic tests. All animals were tested for the presence of anti-DENV IgM by
the IgM antibody capture enzyme-linked immunosorbent assay in order to pre-
clude recent natural infections in the monkeys. To preclude past infections, IgG
antibody tests were performed using a quantitative enzyme-linked immunosor-
bent assay. Neutralizing antibodies to DENV-1 were quantified using a flow
cytometry-based neutralization (FNT) assay on Vero cells. This neutralization
assay is based on a fluorescence-activated cell sorter (FACS)-based dengue virus
titration assay as described previously (63). In the flow cytometry-based neutral-
ization assay, the ability of immune serum to neutralize the infectivity of DENV
on Vero cells is measured at 24 h postinfection by enumerating cells that are
positive for intracellular staining of DENV E protein by flow cytometry.
The neutralization titer for each serum sample was expressed as the reciprocal
of the highest dilution of serum that neutralized the challenge virus by 50%
(FNT50) (63). Alanine aminotransferase and aspartate aminotransferase levels
were determined using a commercial system (Dimension Expand; Dade Behring,
Deerfield, IL).
Isolation of B cells and macrophages from PBMC. PBMC were obtained as
described above and separated by magnetic sorting using superparamagnetic
microbeads according to the manufacturer’s instructions (all reagents and equip-
ment for magnetic cell separation were purchased from Miltenyi Biotec, Auburn,
CA). Macrophages were purified with anti-CD14 microbeads using LS columns.
PBMC were CD3 depleted with the CD3 MicroBead kit using LD columns. B
cells were subsequently purified with anti-CD20 microbeads using LS columns.
The remaining fraction of PBMC and the eluted fraction from the CD3 depletion
(which includes CD4, CD8, NK, and other cells) were labeled as other cells (OC)
and kept frozen at 80°C for further analysis. The cells’ purity was determined
by FACS analysis using conjugated mouse anti-human monoclonal antibodies
known to cross-react with rhesus monkey antigens. CD20 fluorescein isothiocya-
nate (2H7) and CD14 fluorescein isothiocyanate (M5E2) were used to label
purified B cells or macrophages, respectively. In both cases, specific antibodies
were combined with CD3 allophycocyanin (SP34-2), and CD20/CD3 or
CD14/CD3 cells were quantified. Antibodies for FACS analysis were obtained
from BD Biosciences (San Diego, CA).
Total cellular RNA preparation. RNA was extracted from 3  105 PBMC or
from 3  106 isolated B cells, macrophages, or OC by using an RNeasy Mini kit
(QIAGEN, Valencia, CA) and eluted in 30 l of RNase-free double-distilled
H2O. For real-time PCR (RT-PCR), RNA was also extracted from frozen
PBMC. The RNA was resuspended in diethyl pyrocarbonate-treated 0.01%
distilled H2O (Ambion, Austin, TX). The quality and quantity of RNA were
estimated by the Agilent Bioanalyzer RNA Nanochip methodology. RNA sam-
ples from macrophages, B cells, and OC were used for microarray, and RNA
from macrophages, B cells, and PBMC was used for RT-PCR.
Affymetrix GeneChip analysis. The Affymetrix protocol used was essentially
described previously (109). Briefly, 100 picomoles of a T7-(dT)24 primer was
added to 10 g total RNA. The primer and RNA were denatured at 70°C for 10
min and placed on ice, and cDNA was then synthesized using SuperScript II
reverse transcriptase (Invitrogen) according to the manufacturer’s instructions.
Reactions were terminated by the addition of EDTA to a final concentration of
30 mM, and samples were placed on ice. An equal volume of phenol-chloroform-
isoamyl alcohol (25:24:1) was added to each cDNA sample and centrifuged at
16,000  g for 2 min. The aqueous upper layer was precipitated with 2.5 M
ammonium acetate and a 2.5 final volume of 100% ethanol. Samples were
centrifuged, and the resulting pellets were extensively washed with 80% ethanol,
air dried, and resuspended in 12 l diethyl pyrocarbonate-treated water. The
in vitro transcription labeling reactions were done using ENZO BioArray
(Affymetrix) to synthesize biotin-labeled cRNA targets. The labeled cRNA was
cleaned using RNeasy Mini kits, and 15 g was hybridized to rhesus macaque
GeneChip arrays (Affymetrix, Santa Clara, CA) containing 56,867 probe sets,
47,400 transcripts, and 38,500 genes. The microarray procedure was performed
at the Expression Analysis Laboratory (Durham, NC) using a GeneChip Scanner
3000 (Affymetrix). Probe intensity values were extracted from the array image
using GCOS software (Affymetrix).
Data analysis. Genes were normalized to the mean of the controls, and data
from corresponding negative controls were selected as a reference to allow the
calculation of infected/uninfected gene expression ratios. Arrays were median
normalized. Genes with low signals (defined as a signal of 100 above the
background) were not considered. The remaining signals were log2 transformed
prior to analysis so that relative increases and decreases in gene expression were
represented on a linear scale. Gene expression profiles (txt version of the CHP
files) were loaded into the GeneSifter microarray data analysis system (VizX
Labs, Seattle, WA). The data were filtered by using the criteria absent (A),
marginal (M), and present (P). To identify highly expressed genes, only genes
with at least a fourfold increase in expression with a P value of 0.05 after t test
and Benjamini and Hochberg correction were selected and displayed as scatter
plots. For hierarchical clustering, only genes differentially expressed with a P
value of 0.005 and called P were included. Analysis was performed individually
for B cells, macrophages, or OC. When data from all three kinds of samples were
grouped in a single project, the sample was considered to be PBMC.
Relative quantification of cytokine mRNA expression levels. Rhesus macaque
cytokines and other gene mRNA levels were determined by RT-PCR as de-
scribed previously (1). For this experiment, RNA isolated from PBMC, B cells,
and macrophages was used. Briefly, samples were tested in duplicate, and the
PCR for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeep-
ing gene and the target gene from each sample were run in parallel on the same
plate. The reaction was carried out on a 96-well optical plate (Applied Biosys-
tems, Foster City, CA) in a 25-l reaction volume containing 5 l cDNA plus 20
l Mastermix (Applied Biosystems). All sequences were amplified using the 7900
default amplification program. PCR conditions and cytokine and other protein
mRNA expression levels were calculated from normalized CT values according
to methods reported previously (1, 2). In the present study, a minimum of two
normal samples for each kind of studied cell (B cells, macrophages, and PBMC)
were analyzed to determine baseline mRNA levels for each cytokine and
protein. The mean value for each cytokine mRNA level of all animals in each
tissue (mean CT) and the statistical analysis were performed as previously
described (2).
DENV RT-PCR. DENV RNA was isolated from aliquots of serum using the
QIAamp Viral RNA Mini kit (QIAGEN, Valencia, CA) to a final volume of 50
l. One hundred nanograms of RNA was used to amplify a 170-bp product in the
capsid gene region of DENV by RT-PCR according to a methodology described
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previously (67). PCR products were separated by 1.5% agarose gel electrophore-
sis and visualized in a GelDoc station using Quantity One software (Bio-Rad,
Hercules, CA).
Rhesus macaque cytokine detection. The detection of 20 nonhuman primate
chemokines and cytokines was performed in a single sample using the Luminex100
system as previously described (25). Serum was collected at days 1, 3, and 5 after
infection. The panel included granulocyte colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, IFN-, IFN-, IL-1	, IL-1Ra, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12 (p40), IL-17, IL-18, monocyte chemoattractant
protein 1, macrophage inflammatory protein la, macrophage inflammatory pro-
tein 1	, RANTES, and TNF-. The raw data (mean fluorescence intensity) from
all the bead combinations tested were analyzed with Master-Plex QT quantifi-
cation software (MiraiBio Inc., Alameda, CA) in order to obtain concentration
values.
RESULTS
Animal infections and serological tests. To better under-
stand immune responses in rhesus macaques, four animals
were infected with a low-passage strain of DENV-1, and two
animals were mock infected with supernatant from uninfected
cells. All infected animals developed specific anti-DENV-1
neutralizing antibodies as measured by FNT. In Fig. 1, the
titers of neutralizing antibodies at 5 and 20 days and then at 5
months after the infection are shown. Twenty days after infec-
tion, all infected animals had neutralizing antibody titers
(FNT50) above 1:80. At 5 months after infection, titers were
higher in three out of four animals. One animal (animal 27S)
showed a decrease in the antibody titer. Viral RNA was de-
tected in serum by PCR 5 days after infection in all except one
animal (Fig. 1). This animal, animal 92R, showed the highest
levels of transcriptional induction of the genes involved in the
innate immune response (data not shown). In particular, the
aspartate aminotransferase level was increased in all animals,
and in one of them (animal AI73), the alanine aminotransfer-
ase level was also increased (data not shown), possibly indicat-
ing different levels of hepatic injury. No other significant signs
of illness were detected after DENV infection in these animals.
Cell separation. The magnetic microbead system was used
to separate the cells. Cells were labeled with antibodies with
known cross-reactivity to rhesus macaques according to the
manufacturer’s instructions. After separation, B cells (CD3/
CD20) from infected animals were 89 to 95.4% pure (aver-
age, 92.75%), while the purity of the same cells isolated from
control animals was 86% to 88.5% (average, 87.2%). Macro-
phage (CD3/CD14) purity was 90.6% to 95.6% (average,
93.1%) and 76% to 90.1 (average, 83.5%) when isolated from
infected and uninfected animals, respectively.
Differential gene expression is cell specific. For microarray
studies, we used RNA collected from different cells 5 days after
infection. RNA from B cells, macrophages, and OC was run
using rhesus macaque chips. Data obtained from all three
kinds of samples were analyzed together and considered to be
PBMC. Figure 2 shows the scattered plots obtained with sam-
ples from different kinds of cells. The overall pattern was
similar for PBMC and macrophages, with more genes down-
regulated than up-regulated (72.29% versus 27.7% and 74.49%
versus 25.50%, respectively), while B cells showed three times
more up-regulated than down-regulated genes (63.06% versus
36.93%). These results showed a cell type-specific effect in
vivo, which can be coherent with the specific role for each type
of cell. However, a common aspect in all cell types was the
intensities of the differential modifications, with a stronger
up-regulation and a limited down-regulation of the affected
genes. Common ontologic pathways such as immune re-
sponses, inflammatory responses, antiviral responses, and de-
fense were activated in all samples (data not shown) (a com-
plete list of ontologic pathways can be found at http://ucm.rcm
.upr.edu/geneexpression.html).
Analysis of gene expression in DENV-1-infected rhesus ma-
caques. Gene expression profiles for rhesus macaques after
experimental infection have not been studied previously. Fol-
lowing the procedure described above, a total of 812, 3,341,
and 3,671 genes were differentially regulated in PBMC, B cells,
and macrophages, respectively (Fig. 2). The complete gene
lists for each type of cell can be reviewed at http://ucm.rcm.upr
.edu/geneexpression.html. To identify specific genes differen-
tially regulated with higher significance, conditions were set to
P values of 0.005 and with signal calls detected as present
(P). With these conditions, the number of up-regulated genes
was set down to 20, 30, and 40 in PBMC, B cells, and macro-
phages, respectively. No down-regulated genes met these strin-
gent conditions. A summary of all these genes is displayed in
Table 1. The newly identified genes can be set apart into three
categories: IFN-/	-stimulated genes (IFN-induced proteins,
IFN-stimulated gene 15 [ISG15], IFN--inducible protein 6-16
[G1P3 or ISG6-16], IFN--inducible transmembrane protein
27 [IFI27], IFN regulatory element 7 [IRF7], and phospholipid
scramblase 1 [PLSCR1]), IFN-/	-induced and virally induced
FIG. 1. Titers of neutralizing antibodies and serum DENV PCR. Specific antibodies to DENV-1 were measured at different points using a flow
cytometry-based neutralization assay. Titers represent the FNT50 values. Twenty days after infection, all infected animals developed titers over
1:80. Five months later, all infected animals except one had neutralizing antibodies over 1:320. PCR for DENV was performed 5 days after the
infection; the presence of the virus in serum was evidenced by this method in all infected animals except animal 92R. This animal showed a higher
level of induction of antiviral genes (see the text for details). None of the mock-infected animals developed neutralizing antibodies or showed
specific DENV PCR bands in serum.
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genes (2
,5
-oligoadenylate synthetase 1 [OAS1], OAS2,
OAS3, Mx1, Mx2, and PRKR), and other genes with known or
unknown antiviral function (cig5 or viperin, CKCL10, and ep-
ithelial-stromal interactor 1 [EPSTI1]). The increase (n-fold)
of selected genes of each group is shown in Fig. 3A. Some of
these genes (ISG15, ISG6, IFI27, EPSTI1, IFIPT-1, OAS, and
viperin) were up-regulated in all three tested samples. ISG15 is
an IFN-/	-induced protein implicated in a process known as
ISGylation (5, 17, 55). Its role in the antiviral response was first
suggested because human influenza B virus was able to inhibit
its conjugation to target proteins (112). Its direct antiviral
activity against Sindbis virus, a member of the Alphaviridae
family, has recently been demonstrated (66). Its role as an
antiflavivirus has been documented in vitro for West Nile virus
(23) and for hepatitis C virus (HCV) both in vitro and in vivo
using chimpanzees as the animal model (10, 49). However,
there was no previous evidence of ISG15 up-regulation in
response to DENV in vitro or in vivo. The role of this protein
in the anti-DENV immune response is reinforced in this work
by the co-up-regulation of two members of the HERC protein
ligase family (RLD5 and RLD6) linked to the ISGylation pro-
cess (see references 24 and 43 and references therein) (Table
1). The up-regulation of ISG6-16 in response to DENV infec-
tion is documented for the first time in this work. This member
of the ISG group has been shown to have an antiapoptotic
function through inhibiting caspase-3 in cancer cell lines (106).
Its role as anti-HCV (9, 113) and its induction after West Nile
virus infection (23) have also been recently demonstrated. The
induction of high levels of IFI27 (ISG12) and its antiviral role
in response to HCV both in vivo and in vitro (9, 49) as well as
its protective role in the development of lethal alphavirus en-
cephalitis in mice have been well recognized (62). It has been
quite interesting to identify the transcriptional activation of the
EPSTI1 gene (Table 1), which has not been linked so far to the
IFN signaling pathway. This gene was first identified as being
highly upregulated in invasive breast carcinomas compared
with normal breast cells (25, 78). More recently, it has been
related to the pathogenesis of systemic lupus erythematosus
(48). In concordance with this work, EPSTI1 and IFI27 were
up-regulated in patients with systemic lupus erythematosus. To
our knowledge, there were no previous reports of EPSTI1
activation after viral infection. Its induction after DENV in-
fection in rhesus macaques will be further investigated.
In contrast to what has been reported for human cells (12,
109), we were unable to detect a significant modification in the
level of cytokine gene transcription after a primary DENV
infection. As shown in Fig. 3B, only a limited level of tran-
scriptional activation was detected for IL-10 and IL-8. These
data were obtained 5 days after infection. However, serum
detection, using antibodies with known cross-reactivity to rhe-
sus macaque cytokines, did not detect the presence of such
cytokines at day 1, 3, or 5 after infection (data not shown).
RT-PCR confirmation of microarray results. From the mi-
croarray data, we attempted to confirm three central genes
associated with IFN induction by RT-PCR: IRF7, OAS, and
Mx. All of them were shown to be up-regulated by this method,
confirming their increased induction found in the microarrays
(Fig. 4). IRF7 was selected for confirmation because of its
crucial role in the induction of the type I IFN response after
viral infection (44–46). In addition to macrophages, this gene
was found to be up-regulated in B cells. The transcriptional
increase (n-fold) was higher by RT-PCR (compare Fig. 3A to
Fig. 4). These variations could be attributable to differences in
sample processing.
Both OAS and Mx proteins were amplified with generic
primers that were unable to discriminate among different sub-
types of these proteins. However, in both cases, an increase in
gene transcription was also detected. As expected from the
microarray data, both genes were activated in all three kinds of
cells compared to baseline. OAS showed a peak of increase
FIG. 2. Scatter plot of signal intensity comparisons of baselines and infected samples. The log of the mean intensity for the groups is plotted.
Genes with fourfold up- or down-regulation and P values of 0.05 are represented. A cell type-specific response is noticeable by the number of
modified genes (771, 3,721, and 3,341 for PBMC, macrophages, and B cells, respectively) and by its distribution according to the profile of
modification (numbers and percentages are indicated). PBMC and macrophages showed a similar pattern of modification, with a higher percentage
of genes being down-regulated. In contrast, in B cells, the higher number of modified genes was up-regulated. Only macrophages showed
down-regulated genes with signals above 1 log. Genes with positive or negative changes are represented by red and green dots, respectively.
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1 CBP/p300-interacting transactivator, with Glu/
Asp-rich carboxy-terminal domain
NC 7.83 NC Protein binding, transcription factor activity
2 10-kDa IFN--inducible protein (CXCL10_1179) NC NC 5.69 Pleiotropic effects, stimulation of monocytes
3 5
 nucleotidase, cytosolic III NC 4.12 NC Nucleotide binding, hydrolase activity
4 CCL3 (chemokine ligand 3) NC 11.93 NC Immune response
5 Chromosome 17 open reading frame 27 NC 4.44 4 Protein binding
6 C-type lectin domain family 1, member B NC 5.53 NC Defense response, transmembrane receptor
activity, response to virus
7 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 5.97 NC NC Innate immune response, protein binding
8 DNA polymerase-transactivated protein 6 NC 8.11 NC DNA replication
9 DTFT5783 (hypothetical protein LOC388352) NC 4.37 NC ?
10 Endothelial cell growth factor 1 (platelet
derived)
NC 6.39 NC Growth factor activity, thymidine
phosphorylase activity
11 EPSTI1 6.13 10.29 4.64 ?
12 FBJ murine osteosarcoma viral oncogene
homolog B
NC 7.89 NC Sequence-specific DNA binding, transcription
factor activity
13 Full-length cDNA clone CS0DK002YF13 of
HeLa cells, Cot25 normalized
NC NC 5.53 ?
14 G1P3, IFN--induced protein (ISG6-16) 5.01 7.17 5.01 Exonuclease activity
15 gb:AY044446.1 DB_XREF  gi:22074157 
Mmu.11363.1 (similar to glutathione)
NC NC 4.22 ?
16 GEN  PRIC285 peroxisome proliferator-
activated receptor alpha-interacting complex
protein 28S
4.29 NC NC ?
17 gi:60301523 DEF  USP18_9254 rhesus
(ubiquitin-specific protease)
NC NC 5.08 Ubiquitin-specific protease
18 Hect domain and RLD5 (HERC family) 11.52 NC 9.63 Ligase activity, ubiquitin-protein ligase activity
19 Hect domain and RLD6 (HERC family) 5.7 NC NC Ubiquitin-protein ligase activity
20 HS-5-8-S rRNA ribosomal DNA complete
repeating unit
NC 5.23 NC ?
21 Hypothetical protein FLJ20035 (no assigned
function)
5.22 NC 5.08 Nucleic acid binding
22 Hypothetical protein LOC129607 (thymidylate
kinase)
15.6 NC 22.17 Kinase activity
23 IBRDC3 (zinc ion binding metal ion binding
protein binding)
NC 4.68 NC ?
24 Immunoglobulin heavy-chain variable region NC 11.74 NC Nucleotide binding, transferase activity,
protein serine/threonine kinase
25 Immunoglobulin kappa constant NC 10.1 NC Antigen binding
26 IFI27 25.95 59.78 17.61 Immune response
27 IFN-induced protein 44 NC NC 12.58 Response to virus
28 INF-induced transmembrane protein 1 13.96 11.73 17.15 Receptor signaling protein
29 IRF7 NC 4.37 NC Transcription factor
30 IFN-induced protein with tetratricopeptide
repeat 1 (IFIT1_6442)
NC NC 17.15 Immune response
31 IFN-induced protein with tetratricopeptide
repeat 2
10.52 NC 6.69 Immune response
32 IFN-induced protein with tetratricopeptide
repeat 3
6.35 NC 10.27 Immune response
33 IFN-induced protein with tetratricopeptide
repeat 4
6.17 NC 6.51 Immune response
34 IFN-induced protein with tetratricopeptide
repeat 5 (IFIT5_6444)
NC NC 5.6 Immune response
35 ISG15 ubiquitin-like modifier 22.85 34.5 18 Immune response
36 Kruppel-like factor 6 NC 4.51 NC Nucleic acid binding
37 Lectin, galactoside-binding soluble 3 binding
protein
NC 6.8 NC Cell adhesion, activation of immune cells
38 Likely ortholog of mouse d11lgp2 4.64 NC 6.95 Nucleotide binding, hydrolase activity
39 Lymphocyte antigen 6 complex, locus E NC 5.24 NC Defense response, glycosylphosphatidylinositol
anchor binding
40 Mx1 5.44 NC 5.7 Immune response, response to virus, GTP-
binding protein
41 Mx2 NC 4.9 5.98 Immune response, response to virus, GTP-
binding protein
Continued on following page
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that duplicated the value detected by microarray. In this case,
the detection of a whole pool of genes could account for these
marked differences. As shown in Table 1, different members of
this family were up-regulated in each type of cell (OAS1 in
macrophages, OAS3 in macrophages and PBMC, and OAS2 in
macrophages, PBMC, and B cells), suggesting a possible cell
type-specific mechanism of activation of this pathway. The
severalfold increases in Mx proteins detected by RT-PCR were
comparable to those detected by microarray, possibly due to
the existence of fewer variants of the proteins of this family. In
summary, the three selected genes (Mx, OAS, and IRF) were
found to be up-regulated upon DENV-1 infection, confirming
their increased induction originally detected by the microarray
method.
The induction of IRF7 was also confirmed by RT-PCR. In
contrast to IRF3, the other key player in the type I IFN path-
way, IRF7 is not constitutively expressed in most cell types, and
it has a short half-life (69, 79, 93, 110). After activation by
phosphorylation, IRF7 is translocated to the nucleus, where it
induces the transcription of IFN-/	 genes (69, 93, 94). These
aspects are very important in our work, because it was detected
5 days after infection with DENV, supporting the presence of
a very recent stimulus. In addition, by the use of RT-PCR, we
were able to confirm the lack of induction of cytokine genes
like IFN-	, IFN-, and TNF- 5 days after in vivo infection
with DENV-1 (Fig. 4). This result was confirmed by cytokine
detection in serum at days 1, 3, and 5 after infection (data not
shown).
DISCUSSION
Presently, there is not an adequate animal model to study
DENV pathogenesis or to test immune responses to DENV
candidate vaccines. Interesting approaches using mice have
been done in recent years (8, 99). It is well known that ma-
caques respond to DENV infection with quite limited signs
and symptoms compared to humans; however, they are the
ultimate model of choice to test DENV vaccine candidates and
their elicited immune responses. Nevertheless, the molecular
basis of the immune response to DENV in macaques is re-
markably unknown, and the continued use of this model re-
quires a better understanding of underlying differences be-
tween human and macaque immune systems. We infected four
rhesus macaques with a low-passage strain of DENV-1, and 5
days thereafter, by using microarrays and RT-PCR, we ob-










42 Mx2 human-like protein NC 4.92 NC Immune response, response to virus,
nucleotide binding, transferase activity
43 OAS1 NC 25.48 NC Nucleotidyltransferase
44 OAS2 7.29 10.76 7.92 Immune response
45 OAS2 (69/71 kDa) NC NC 6.83 Immune response, nucleotidyltransferase,
ATP/RNA binding
46 OAS3 4.2 16.62 NC Immune response
47 Platelet factor 4 (CXCL4 variant 1) NC 10.51 NC Immune response, chemokine activity
48 Platelet factor 4 (CXCL4) NC 5.57 NC Leukocyte chemotaxis, immune response,
chemokine activity
49 Platelet-derived endothelial cell growth factor/
thymidine phosphorylase
NC 4.61 NC ?
50 PRKR NC NC 4.16 Immune response, response to virus, negative
regulation of cell proliferation
51 PTX3_4 pentaxin-related gene NC 5.73 NC Inflammatory response
52 Schlafen family member 5 NC NC 8.74 DNA/RNA helicase
53 Scramblase 1 NC 4.11 NC Response to virus, protein binding
54 Serum/glucocorticoid-regulated kinase NC 5.95 4.5 Nucleotide binding, protein/serine/threonine
kinase activity
55 STAT, 1.91 kDa (STAT1) NC NC 5.01 Transcription factor
56 Similar to MGC52679 NC 4.61 NC Phosphorylase activity
57 Sterile alpha motif domain-containing 9 NC 6.14 NC Binding
58 Syndecan 3 (N-syndecan) NC 4.11 NC Cytoskeletal protein binding
59 Thymidylate kinase activity 15.6 NC NC Kinase/transferase activity
60 Tribbles homolog 2 (Drosophila melanogaster) NC 4.84 NC Nucleotide binding, protein kinase activity,
protein kinase inhibitor activity
61 Tripartite motif-containing 14 (TRIM14) NC NC 4.24 Protein binding, metal/zinc ion binding
62 Tumor necrosis factor (ligand) superfamily,
member 10 (TNFSF10)
NC 5 NC Immune response, apoptosis, TNF receptor
binding
63 Unc-93 homolog B1 (Caenorhabditis elegans) NC 5.27 NC ?
64 Radical S-adenosyl methionine domain-
containing 2 (cig5, viperin)
11.96 12.49 15.47 Catalytic activity, iron ion binding/antiviral
a Genes that were increased by 4.0-fold or greater were included. Conditions for this set of genes were a P value of 0.005 and call P. Twenty, 40, and 30 genes were
detected under these conditions in PBMC, macrophages (MO), and B cells (BC), respectively. Gene names are given at the left and are organized alphabetically. The
function attributable to each gene is given on the right. Information on how to access the full list of all genes, specific P values, and ontologic pathways is provided in
the text. NC, no changes.
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serum cytokines was studied by multiplex cytokine detection
after 1, 3, and 5 days of infection.
We found a robust innate immune response characterized by
the induction of several genes implicated in the immune re-
sponse to viral infections. Most of those genes were ISGs and
virus-induced genes. A third group included some genes with
no relation to the IFN signaling pathway. By RT-PCR, we
confirmed that at least three of those genes (IRF7, OAS, and
Mx) were indeed up-regulated.
2
,5
-Oligoadenlyate is a system that is well documented as
an endogenous player in the antiviral pathway (16, 89, 92). This




-linked oligoadenylates, whose function is to activate
RNase L with subsequent RNA degradation. The implication
of this system to control flavivirus infections has been demon-
strated before in vitro and in vivo for West Nile virus (54, 70,
95) and HCV (56, 68, 75) and in vitro for DENV (109). Our
finding in vivo of increased levels of OAS transcripts confirms
the role of this system in controlling DENV replication in
rhesus macaques.
The Mx protein family is well known for its role in antiviral
responses in vivo and in vitro (31, 65, 80, 81), and the proteins
are preferentially induced by IFN-/	 (20). Evidence from
animal studies established that Mx alone is sufficient to block
the replication of virus in the absence of any other IFN-/	-
inducible proteins (3, 30). The induction of Mx1, Mx2, and
MxA genes was produced after in vitro infection of HUVEC
cells with DENV-2 (110); however, in our study, only Mx1 and
Mx2 were detected as being up-regulated by microarrays.
These results together confirm the specific anti-DENV activity
of Mx proteins.
In contrast with other key players in the type I IFN pathway
such as IRF3, IRF7 is not constitutively expressed in most cell
types, and it has a short half-life (69, 79, 93, 110). After acti-
vation by phosphorylation, IRF7 is translocated to the nucleus,
where it induces the transcription of IFN-/	 genes (69, 93,
94). The detection of high levels of IRF7 5 days after the
FIG. 3. Transcriptional increase (n-fold) detected by microarray. Selected genes were plotted for comparative purposes among samples and
among genes. (A) Increment of the ISGs. The IFI27 and ISG15 genes were the most highly up-regulated, followed by the OAS genes Mx, viperin,
and EPSTI1. (B) Transcriptional modifications of the cytokine genes. Only a limited increase in the transcription levels of IL-10 and IL-8 was
detected. IFN- was detected as being down-regulated in all kinds of samples. However, none of these changes were statistically significant,
reflecting no changes in the transcriptional activity of these genes. The transcriptional increase (n-fold) was plotted on the abscissa. The names
of the genes are shown on the ordinate.
FIG. 4. Real-time confirmation of ISG gene but not of cytokine
gene up-regulation. Three ISG genes (IRF7, OAS, and Mx) and three
cytokine genes (IFN-, TNF-, and IFN-	) were selected to be am-
plified by RT-PCR to confirm the microarray data. Figures represent
increases (n-fold) in up-regulated genes compared to baseline samples.
All three ISGs were up regulated except IRF7 in PBMCs. No increase
in the transcription level of the studied cytokine genes was detected.
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infection with DENV-1 in rhesus monkeys could then be in-
terpreted as evidence of the presence of a very recent stimulus.
This is particularly remarkable in the lack of confirmed cyto-
kine induction, including IFN-	, IFN-, and TNF-, 5 days
after DENV-1 infection (Fig. 4). These results were confirmed
by cytokine detection in serum at days 1, 3, and 5 after infec-
tion (data not shown).
One of the key and unexpected outcomes of this study was
the apparent lack of induction of three key cytokines in human
innate immunity: IFN-	, IFN-, and TNF- (Fig. 3 and 4). In
addition, only limited but not significant up-regulation of IL-10
and IL-8 was detected by microarray, (Fig. 3). This is highly
contrasting with what has been reported for humans. The high-
level presence of IL-10, IL-8, IL-6, TNF-, and IFN- is a
hallmark of the development of DHF/DSS and has been asso-
ciated with an increased risk of developing severe forms of
disease in primary infections, which may be accentuated during
secondary infections (7, 13, 18, 28, 40–42, 50, 52, 53, 64, 82, 86).
Several groups documented an increased production of these
proinflammatory cytokines after a primary infection (6, 7, 13,
50, 64, 77, 83, 108), even in cases without DHF/DSS manifes-
tations (6, 64, 77, 83, 108).
Because our study was performed 5 days after infection, we
cannot rule out later cytokine gene induction and cytokine
production. One of the advantages of the macaque model is
that we have the opportunity to analyze the very early virus-
host interaction, which is often not possible for humans.
DENV is able to induce the activation of PBMC in mice as
early as 3 days after infection (97) and in humans with less than
72 h of fever/viremia (27). Also, the production of cytokines
has been detected in children presenting less than 72 h of fever
(26–28, 60). Considering that disease outcome is likely to be
decided by those early events, it is remarkable that we were
unable to find the inflammatory response that is so typical for
disease in humans. Nevertheless, in the future, we plan to
conduct similar studies at later time points following infection.
Our new findings may explain why rhesus macaques do not
develop DF or DHF/DSS after a primary DENV infection.
Indirectly, these results confirm the proposed role of TNF-
and IFN- in the development of DHF/DSS. Thus, it might be
argued that a therapy aimed at the suppression of inflamma-
tion/activation may reduce the incidence of DHF/DSS in hu-
mans. It can be affirmed that a different profile could be ex-
pected after a secondary infection of these animals. However,
our data show that the cytokine profile after secondary infec-
tion with DENV-2 is very similar to the one described after
primary infection (C. A. Sariol et al., unpublished results).
The up-regulation of OAS and Mx proteins shown by mi-
croarrays and RT-PCR was expected, as they constitute a stan-
dard response after infection with several viruses (3, 30, 47, 54,
92, 103, 109, 110) and are a confirmation of the role of the
innate immune response generated after DENV infection in
macaques. The increased detection by both methods reinforces
the importance of this type of immune response in controlling
DENV replication in rhesus macaques. Additionally, several
ISGs such as ISG15 and ISG16-56, which are acting during the
innate immune response, were found to be highly up-regulated
by microarrays.
Induction of ISGs without increased levels of type I or type
II IFN has been reported for HCV-infected chimpanzees (10).
Similar to data from that report, we found an apparent con-
tradiction in that the induction of ISGs may not necessarily be
accompanied by a higher induction of IFN. Additionally, in-
creases in serum levels of IFN- or IFN- were not detected by
the multiplex cytokine array even as early as 24 h after the
infection (data not shown). However, the following explana-
tions for the apparent discrepancy may account for this fact.
An early transcriptional activation of these genes before the
day of the sampling for microarray and RT-PCR study (5 days
after infection) with a restricted level of expression below the
limit of detection of our assay but still able to stimulate the ISG
transcription detected 5 days later may have occurred. Second,
only the first wave of the IFN response, characterized by the
production of IFN-	 (69, 93, 94), was allowed to occur (animal
or virus restriction). Because of the lack of a reagent with
reactivity for this rhesus macaque cytokine (IFN-	), we were
unable to test its levels in serum, and we were missing a crucial
and early-phase activation of the innate immune response. For
the same reasons, we may be missing the possible expression of
IFN-, which has been shown to have an active role in the
activation of the immune response (57, 96). Third, anti-IFN
activity of DENV protein NS4B through the inhibition of the
Janus kinase (JAK)/signal transducer and activator of tran-
scription (STAT) pathway has been documented in vitro using
monkey kidney cells (72, 73). This mechanism may lead to the
partial impairment of the IFN pathway. Fourth, novel virus-
host interactions may limit the transcriptional activation and
expression of IFN- and IFN- and other cytokines, such as
TNF-, IL-6, IL-8, and IL-10, linked to the immunopathogen-
esis of DENV.
The detection of IRF7 up-regulation by microarray and con-
firmation by RT-PCR 5 days after infection also support the
existence of alternative mechanisms in this animal model to
regulate type I IFNs and activate ISGs. The role of IRF7 as a
master regulator in the induction of type I IFN is well known
(44–46). It was long believed that the activation of IRF7 was
dependent exclusively on basal levels of IFN-/	 or in response
to an early wave of IFNs following virus infection, which in
turn amplified IFN-/	 production through the increase in the
intracellular level of IRF7 (69, 76, 93, 94, 107). However, it has
recently been shown that the regulation of IRF7 transcription
includes a virus-dependent but IFN-independent signaling
pathway (79). In such alternative mechanisms, the viral infec-
tion induces virus-activated factor complex formation (includ-
ing IRF7/IRF3), which directly binds to specific regions of the
IRF7 promoter. One essential component of this pathway is
the recruitment of cyclic AMP response element binding pro-
tein (CREB)-binding protein (CBP)/p300 for IRF3 activation
(79). However, it has also been shown that this activator has an
opposing activity by negatively modulating the IRF7 DNA
binding (14). Supporting this mechanism in our model, as an
alternative induction of IRF7 without detectable transcrip-
tional activation or serum levels of type I IFN, is the transcrip-
tional up-regulation of the CBP/300 gene detected by microar-
ray (Table 1). It could act in synergy with the anti-IFN activity
of the nonstructural proteins of DENV, particularly NS4B
through the JAK/STAT pathway (39, 51, 72, 73). Although we
have no data to support the occurrence of this mechanism in
vivo in our model, it is an alternative to be addressed in further
studies.
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Other genes such as PLSCR1 or EPSTI1, here detected as
being up-regulated by microarray, are also interesting targets
for further studies. PLSCR1 is a membrane protein implicated
in the synthesis and translocation of phospholipids to the cell
surface in response to cell activation, injury, or apoptotic stim-
ulus (111), and it is able to strengthen the antiviral activity of
IFNs (19). This gene was previously found to be activated after
DENV-2 infection in HUVEC cells (109). Our in vivo results
support the anti-DENV activity of this protein. Confirmation
of the up-regulation of EPSTI1 by other methods will be per-
formed.
The immune response to DENV described in this work is
quite different from the immune response characterized in
mice (4, 97–100) and in humans in vivo or in vitro using human
cells (12, 13, 15, 18, 41, 83, 99, 104, 109). This strongly suggests
interspecies differences in the complex molecular mechanisms
of the IFN response. This reinforces the need to search for a
proper animal model to study the pathogenesis and immune
response to vaccines against DENV.
This balance of innate immune response without cytokine
induction can be an example of a long-term host-parasite evo-
lutionary process. Similar situations have been demonstrated
for sooty mangabeys infected with simian immunodeficiency
virus. These animals are naturally infected without developing
symptoms. The key feature of that process is a controlled
activation of the immune response (74, 101).
Results documented in this work prompted us to consider
other interventions in addition to vaccine approaches, like the
modulation of the innate immunity, to control the develop-
ment of severe forms of this disease.
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